LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma

Multiple myeloma (MM) remains an incurable hematological malignancy. Despite tremendous advances in the treatment, about 10% of patients still have very poor outcomes with median overall survival less than 24 months. Our study aimed to underscore the critical mechanisms pertaining to the rapid dise...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Lixin Gong, Hao Sun, Lanting Liu, Xiyue Sun, Teng Fang, Zhen Yu, Weiwei Sui, Jingyu Xu, Tingyu Wang, Fangshuo Feng, Lei Lei, Wei Rui, Yuxuan Liu, Xueqiang Zhao, Gang An, Xin Lin, Lugui Qiu, Mu Hao
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Ferrata Storti Foundation 2024-05-01
Цуврал:	Haematologica
Онлайн хандалт:	https://haematologica.org/article/view/11626
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!